Food and Drug Administration approval of buprenorphine-naloxone for office treatment of addiction.
Resnick
Richard B
RB
D002047:Buprenorphine / Q000627:therapeutic use*; D017277:Drug Approval; D004338:Drug Combinations; D006801:Humans; D009270:Naloxone / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D009293:Opioid-Related Disorders / Q000188:drug therapy*; D011331:Private Practice; D014481:United States; D014486:United States Food and Drug Administration
D004338:Drug Combinations; D009292:Narcotic Antagonists; D009270:Naloxone; D002047:Buprenorphine